Litigation Details for Shire Development LLC v. Alkem Laboratories Ltd. (D. Del. 2016)

Shire Development LLC v. Alkem Laboratories Ltd. (D. Del. 2016)

Docket		Date Filed	2016-08-24
Court	District Court, D. Delaware	Date Terminated	2017-03-21
Cause	35:183 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To	Christopher J. Burke
Patents	7,465,465; 8,980,327; 9,023,397
Link to Docket	External link to docket

Details for Shire Development LLC v. Alkem Laboratories Ltd. (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-08-24				External link to document
2016-08-24	35		2017, do not infringe United States Patent Nos. 5,968,976, 7,465,465, 8,980,327, and 9,023,397. …judgment that any claim of any of the asserted patents is invalid or unenforceable. 4. All …2016 21 March 2017 1:16-cv-00747 830 Patent None District Court, D. Delaware	External link to document
2016-08-24	36		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,968,976; 7,465,465; 8,980,327; 9,023,397…2016 21 March 2017 1:16-cv-00747 830 Patent None District Court, D. Delaware	External link to document
2016-08-24	4		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,968,976; 7,465,465; 8,980,327; 9,023,397…2016 21 March 2017 1:16-cv-00747 830 Patent None District Court, D. Delaware	External link to document

Shire Development LLC v. Alkem Laboratories Ltd.: Litigation Summary, Lialda Patent Claims, and Generic Entry Risk

Last updated: August 11, 2026

Shire Development LLC v. Alkem Laboratories Ltd., No. 1:16-cv-00747-RGA, was a Hatch-Waxman patent action in the U.S. District Court for the District of Delaware involving Alkem’s abbreviated new drug application for generic mesalamine delayed-release tablets, the generic equivalent of Shire’s Lialda product. Shire asserted Orange Book-listed formulation patents after receiving Alkem’s Paragraph IV certification. The case ended without a reported merits judgment, published claim-construction ruling, or publicly available finding that the asserted patents were valid and infringed.

The case was dismissed pursuant to a settlement-related stipulation. The public docket does not disclose the material commercial terms, including any authorized generic rights, launch date, or royalty provisions. The principal business consequence was therefore a private resolution of Alkem’s potential generic-entry challenge rather than a judicial determination of Lialda patent strength.

What drug and patents were involved in Shire v. Alkem?

The litigation involved Lialda, an extended-release oral mesalamine product used to induce and maintain remission in ulcerative colitis. Lialda uses a multimatrix delivery system intended to release mesalamine throughout the colon.

Item	Detail
Brand product	Lialda
Active ingredient	Mesalamine, also called 5-aminosalicylic acid or 5-ASA
Dosage form	Delayed-release oral tablet
Brand sponsor at the time	Shire Development LLC and affiliated Shire entities
Generic applicant	Alkem Laboratories Ltd.
Regulatory pathway	ANDA under the Hatch-Waxman Act
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:16-cv-00747-RGA
Filing period	2016
Disposition	Dismissed following a settlement-related stipulation
Merits ruling	No reported final merits judgment

The complaint followed Alkem’s Paragraph IV certification that one or more patents listed for Lialda were invalid, unenforceable, or would not be infringed by Alkem’s proposed product. Under 21 U.S.C. § 355(j)(5)(B)(iii), the filing of the patent action generally triggers a statutory stay of FDA approval for up to 30 months, subject to statutory exceptions and court action.

What patents protected Lialda in the Alkem litigation?

Publicly available case and patent records identify the action as a Lialda mesalamine formulation dispute. The relevant patent estate included patents directed to controlled-release and multimatrix mesalamine tablets, including U.S. Patent Nos. 8,865,688 and 8,945,608. The broader Lialda patent portfolio also included earlier and later patents covering the composition, release profile, and manufacturing characteristics of mesalamine tablets.

Formulation patents

The central technology was a multimatrix formulation. The system generally combines mesalamine with hydrophilic and lipophilic excipients in a tablet designed to resist release in the upper gastrointestinal tract and release active ingredient at higher-pH intestinal conditions.

The commercial importance of these patents was greater than the relatively simple chemical identity of mesalamine suggests. Mesalamine itself is an established active ingredient with limited composition-of-matter protection. The principal barriers to generic substitution therefore arose from:

1. The tablet’s release architecture.
2. The specific excipient matrix.
3. Coating and dissolution characteristics.
4. Manufacturing processes used to produce the controlled-release dosage form.
5. Orange Book-listed method-of-use or formulation claims.

Patent-estate structure

Protection category	Relevance to Lialda
Active ingredient	Weak or expired protection because mesalamine is an established compound
Multimatrix formulation	Core protection for the Lialda dosage form
Controlled release	Covers release behavior and gastrointestinal delivery
Manufacturing process	May create non-infringement and design-around issues
Method of use	Can remain relevant after formulation patents expire if properly listed and enforceable
Regulatory listing	Orange Book listing supports a Paragraph IV litigation pathway

Patent expiration dates must be reviewed patent by patent because effective dates can change based on patent-term adjustment, patent-term extension, terminal disclaimers, and regulatory exclusivity. The Lialda formulation patents generally created an effective patent barrier into the late 2020s, although not every patent in the portfolio necessarily had the same expiration date or claim scope.

How did Alkem’s Paragraph IV challenge affect FDA approval?

Alkem’s ANDA certification created the legal basis for Shire’s patent action. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed by the proposed generic product. It does not mean the FDA has found the patent invalid. It is a statutory litigation position taken by the ANDA applicant.

The filing of Shire’s complaint likely triggered the Hatch-Waxman 30-month stay for the patents identified in the litigation, unless the stay was shortened, terminated, or otherwise affected by a court order or regulatory event. During the stay, FDA review of the ANDA could continue, but final approval generally could not issue while the statutory stay remained in effect.

The practical approval scenarios were:

Scenario	Commercial result
Shire wins and obtains an injunction	Alkem’s launch is blocked until patent expiry or settlement-authorized entry
Alkem wins on invalidity or non-infringement	FDA approval can proceed after regulatory requirements are satisfied
Parties settle	Entry date and commercial rights depend on confidential settlement terms
Patent claims are narrowed or disclaimed	Alkem may retain a pathway to approval or redesign
Regulatory exclusivity ends before patent barriers	FDA approval remains constrained by patent litigation

The public disposition does not show a reported adjudication resolving these issues.

What was the litigation timeline in Shire v. Alkem?

Date or period	Event
Before 2016	Alkem submitted an ANDA for generic mesalamine delayed-release tablets and certified against Lialda patents
2016	Shire filed Civil Action No. 1:16-cv-00747 in the District of Delaware
2016 to 2017	The parties litigated the patent claims and regulatory consequences of Alkem’s ANDA
2017	The action was resolved through a settlement-related dismissal
After dismissal	No public merits judgment established infringement or invalidity in this case

The case was assigned to Judge Richard G. Andrews. The docket did not produce a published claim-construction opinion comparable to the decisions that later shaped other Lialda-related patent disputes.

Was there a final judgment on patent validity or infringement?

No reported final merits judgment appears in the case. The public record does not establish that the court held any asserted patent valid, infringed, invalid, or unenforceable.

This distinction matters. A dismissal after settlement does not validate the asserted patents. It also does not establish that Alkem’s proposed product infringed them. The case therefore has limited precedential value for later Lialda litigation, although the asserted patents and the parties’ litigation positions remain relevant to patent-risk analysis.

The case should be classified as a commercial Hatch-Waxman resolution rather than a judicial patent win.

What was the settlement status and did Alkem receive a launch date?

The case was dismissed pursuant to a settlement-related filing, but the material settlement terms were not publicly disclosed in the docket record. There is no reliable public basis in the case record to state that Alkem received:

• A specific authorized launch date.
• A license to launch before patent expiry.
• Authorized generic supply rights.
• A royalty-bearing license.
• A covenant not to sue covering additional patents.
• A waiver of future patent claims.
• A manufacturing or distribution arrangement with Shire.

Confidential settlements are common in ANDA litigation. Their economic effect can range from a launch license several years before patent expiry to a near-expiry date that preserves most of the brand’s remaining revenue.

The absence of disclosed terms prevents the case from being used as evidence of a particular Alkem launch date.

What is the Orange Book status of Lialda?

Lialda’s Orange Book position depended on the patents listed for the specific strength and dosage form. The relevant listings were formulation-oriented rather than based on a new chemical entity.

The Orange Book is important because it identifies patents that an ANDA applicant must address through one of four certifications:

1. Paragraph I: no patent information has been filed.
2. Paragraph II: the patent has expired.
3. Paragraph III: the applicant will wait until patent expiry.
4. Paragraph IV: the patent is invalid, unenforceable, or not infringed.

A Paragraph IV certification can create litigation even when the generic applicant believes its product differs from the brand product. The infringement analysis focuses on the patent claims and the proposed ANDA product, including its formulation, manufacturing process, labeling, and release profile.

Orange Book listings do not independently prove that a patent is valid or infringed. They create a statutory mechanism for resolving the dispute before commercial approval.

How strong was Shire’s Lialda patent estate?

The estate had moderate-to-strong commercial leverage but mixed legal characteristics.

Strengths

The estate covered the product’s principal commercial differentiator, namely controlled release of mesalamine through a multimatrix tablet. Formulation patents can be difficult to avoid when the generic applicant must demonstrate pharmaceutical equivalence and comparable dissolution performance.

The estate also benefited from multiple patent families and staggered filing dates. A generic applicant could defeat one patent and still face exposure from another patent covering a related formulation or use.

Weaknesses

Mesalamine is an old and widely used active ingredient. The core chemical compound did not provide a durable exclusivity barrier. Generic applicants could focus on obviousness, written-description, enablement, claim construction, and non-infringement arguments directed to the formulation claims.

The more narrowly a patent claim describes the matrix, excipient ratio, coating, or release profile, the greater the potential for a design-around. Conversely, broader formulation claims face greater validity risk based on earlier mesalamine and controlled-release technology.

Because Shire v. Alkem ended without a merits ruling, it did not resolve the balance between these strengths and weaknesses.

What generic-entry risks existed for Lialda?

The main generic-entry risks were:

Risk	Assessment
Paragraph IV litigation	Material, because Alkem challenged listed Lialda patents
Early generic launch	Dependent on settlement terms and patent status
Multiple ANDA filers	Increased pressure on the patent estate and potential price erosion
Formulation design-around	A significant legal and technical issue
Authorized generic competition	Possible but not established by the public record
At-risk launch	Limited evidence in this case; no public merits ruling supports one
Biosimilar substitution	Not applicable; Lialda is a small-molecule drug
Revenue erosion	Potentially substantial after first generic entry because mesalamine tablets are administratively substitutable

Biosimilar risk was not relevant. Lialda is a chemically synthesized small-molecule product regulated through the ANDA pathway, not a biologic regulated under the Public Health Service Act.

Which companies challenged Lialda patents?

Lialda faced broader generic competition than the Alkem case alone indicates. Shire pursued multiple ANDA litigations involving generic applicants seeking approval for mesalamine delayed-release tablets. The competitive field included major generic manufacturers and international pharmaceutical companies that could challenge formulation patents through Paragraph IV certifications.

The commercial effect of the first approved generic would depend on:

• Whether the first applicant had 180-day exclusivity.
• Whether other ANDAs were eligible for approval at the same time.
• Whether the settlement agreements permitted staggered entry.
• Whether an authorized generic was launched.
• The extent of pharmacy substitution under state law and payer formularies.
• The price discount relative to branded Lialda.

How did Shire v. Alkem affect Shire revenue exposure?

The case exposed Lialda revenue to the standard first-generic erosion pattern. Before generic entry, Shire could preserve branded pricing through formulary positioning, physician familiarity, and the lack of an approved therapeutically equivalent alternative. After generic entry, pharmacy substitution and payer pressure could reduce both volume and net price.

The revenue impact would be determined less by the filing of the lawsuit than by the settlement’s effective entry date. A settlement allowing entry several years before the last enforceable patent could produce substantial value transfer from the brand to the generic applicant. A settlement limiting entry to a date close to patent expiry would preserve more of the product’s lifecycle revenue.

Because the Alkem settlement terms were not public, the case cannot support a precise revenue-loss calculation.

What is the current legal significance of the case?

The case has limited precedential significance. It is useful for identifying:

• Alkem’s ANDA challenge to Lialda.
• The asserted Lialda formulation-patent framework.
• The existence of Hatch-Waxman litigation involving Shire and Alkem.
• The resolution of the dispute without a public merits opinion.

It is not a controlling authority on the validity, enforceability, or infringement of the Lialda patents. Analysts should not characterize the dismissal as a patent victory for Shire or Alkem.

Key Takeaways

• Shire Development LLC v. Alkem Laboratories Ltd., No. 1:16-cv-00747-RGA, concerned Alkem’s ANDA for generic mesalamine delayed-release tablets.
• The underlying brand was Lialda, an extended-release mesalamine product for ulcerative colitis.
• Shire relied on formulation and controlled-release patent protection rather than durable compound protection.
• Alkem used a Paragraph IV certification, creating Hatch-Waxman litigation risk and a potential 30-month FDA approval stay.
• The case ended through a settlement-related dismissal.
• No reported merits decision determined whether the asserted patents were valid, infringed, or enforceable.
• The public docket does not disclose Alkem’s launch date, authorized generic rights, royalties, or other material settlement terms.
• Biosimilar risk was irrelevant because mesalamine is a small-molecule drug regulated through the ANDA pathway.
• The case is commercially important but has limited precedential value.

FAQs About Shire v. Alkem and Lialda Patent Litigation

Did Alkem win the Shire Lialda patent case?

No judicial ruling awarded Alkem a victory on invalidity or non-infringement. The action ended through a settlement-related dismissal without a reported merits judgment.

Did Shire obtain an injunction against Alkem?

No publicly reported permanent injunction or merits-based preliminary injunction appears in the case record.

Did the Lialda patents cover mesalamine itself?

The principal patents at issue were formulation and delivery patents. They did not provide the same type of protection as a basic composition-of-matter patent covering the mesalamine molecule.

Was Alkem’s Lialda generic approved by the FDA?

The litigation docket does not establish the final FDA approval status or commercial launch date of Alkem’s ANDA. FDA approval and patent settlement status are separate regulatory and legal questions.

Could a generic manufacturer design around the Lialda patents?

Potentially. A design-around would depend on the exact patent claims, the generic formulation, dissolution testing, labeling, and manufacturing process. The absence of a merits ruling in Shire v. Alkem leaves those issues unresolved in this case.

References

1. U.S. District Court for the District of Delaware. (2016). Shire Development LLC v. Alkem Laboratories Ltd., No. 1:16-cv-00747-RGA. PACER docket.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov/drugs/guidance-compliance-regulatory-information

4. U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term information. https://www.uspto.gov/patents/laws/patent-term-adjustment

5. U.S. Code, 21 U.S.C. § 355(j). (2024). Abbreviated applications for new drugs. https://uscode.house.gov/~~~